🔎 Trials Near Me

Dachaigh › Tumairean Neuroendocrine › Nebraska

Sgrùdaidhean clionaigeach Tumairean Neuroendocrine ann an Nebraska

Tha 6 sgrùdaidhean airson Tumairean Neuroendocrine a’ lorg phàirtichean aig làraichean ann an Nebraska.

Bailtean ann an Nebraska

Teacsa sgrùdaidh oifigeil (Beurla)

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  • University of Nebraska Medical Center, Omaha
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT06943755

Project: Every Child for Younger Patients With Cancer

  • Children's Hospital and Medical Center of Omaha, Omaha
  • University of Nebraska Medical Center, Omaha
A’ fastadhSgrùdadh amharc
Suas gu aois 25 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT02402244

Integrated Cancer Repository for Cancer Research

  • Mary Lanning Healthcare, Morrison Cancer Center, Hastings
  • Faith Regional Health Services, Carson Cancer Center, Norfolk
  • Great Plains Regional Medical Center, North Platte
  • agus 3 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 19 gu 110 · Gach gnè · Air ùrachadh 29 Ògmh 2026 · NCT02012699

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

  • Nebraska Cancer Specialists, Omaha
A’ fastadhÌre 1/2
Aoisean 18 gu 90 · Gach gnè · Air ùrachadh 14 Cèit 2026 · NCT05636618

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

  • Research Facility, Omaha
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Màrt 2026 · NCT05477576

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Omaha
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 28 Dàmh 2025 · NCT03452774

Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.